Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
3.050
-0.060 (-1.93%)
At close: Nov 19, 2026, 4:00 PM EST
3.060
+0.010 (0.33%)
After-hours: Nov 19, 2026, 7:30 PM EST
Bicycle Therapeutics Revenue
Bicycle Therapeutics had revenue of $34.06M in the quarter ending September 30, 2026, with 190.24% growth. This brings the company's total for the last twelve months to $83.53M, up 194.75% year-over-year. In the year 2025, Bicycle Therapeutics had annual revenue of $72.59M with 105.77% growth. That makes Bicycle Therapeutics the 24,114th largest company in the world by revenue and 3,414th in the United States.
Revenue (ttm)
$83.53M
Revenue Growth
+194.75%
P/S Ratio
2.56
Revenue / Employee
$290,028
Employees
288
Market Cap
213.79M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 72.59M | 37.31M | 105.77% |
| Dec 31, 2024 | 35.28M | 8.30M | 30.76% |
| Dec 31, 2023 | 26.98M | 12.51M | 86.52% |
| Dec 31, 2022 | 14.46M | 2.77M | 23.65% |
| Dec 31, 2021 | 11.70M | 1.31M | 12.58% |
| Dec 31, 2020 | 10.39M | -3.41M | -24.72% |
| Dec 31, 2019 | 13.80M | 6.67M | 93.40% |
| Dec 31, 2018 | 7.14M | 5.08M | 246.41% |
| Dec 31, 2017 | 2.06M | - | - |
| Dec 31, 2016 | 0 | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 229.28M |
| Keros Therapeutics | 40.76M |
| vTv Therapeutics | 36.84M |
| Arcturus Therapeutics Holdings | 30.51M |
| AC Immune | 23.75M |
BCYC News
- 21 days ago - Bicycle Therapeutics reports Q3 EPS (15c), consensus (46c) - TheFly
- 21 days ago - Bicycle Therapeutics sees cash runway into 2030 - TheFly
- 21 days ago - Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results - Business Wire
- 21 days ago - Bicycle Therapeutics Earnings release: Q3 2026 - Filings
- 21 days ago - Bicycle Therapeutics Quarterly report: Q3 2026 - Filings
- 1 month ago - Bicycle Therapeutics treatment of pancreatic cancer granted orphan designation - TheFly
- 3 months ago - Visa Inks $2.4 Billion Deal to Acquire Fraud Prevention Firm BioCatch - PYMNTS
- 3 months ago - Bicycle Therapeutics assumed with an Outperform at Oppenheimer - TheFly